Assessment of the role of Adipsin and Hepassocin as biomarkers in males with untreated hypothyroidism and diabetes
Article Sidebar
Main Article Content
Abstract
Thyroid hormones are closely linked to metabolic and many physiological processes in the human body. Therefore, it is expected that hypothyroidism, which is a common disease in the world, is linked to many diseases such as diabetes, liver diseases, and everything related to metabolic processes. Therefore, we also expect a link between the difference in concentrations of biochemical variables such as heparin and adipsin in the bloodstream for patients with hypothyroidism and other diseases. All sixty men patients were suffering from hypothyroidism, their ages ranged from 30 to 61 years old. After collecting the samples, thyroid hormone concentrations in blood serum were measured using the Minividas technique, while heparin and adipsin were measured using kits from Sun Long Biotech (China). There was a highly significant increase (P≤0.001) in Thyroid-Stimulating Hormone (TSH), vasopressin, and adipsin levels in the men's patient group compared to healthy men in the control group. The results showed a highly significant decrease (P≤0.001) in T4 compared with the men's control group. Hepassocin and adipsin may be relatively independent good markers for the prognosis of an active thyroid gland “hypothyroidism”.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
1. Otla AA, Saleh NA. Estimation of the level of homocysteine and vitamin B12 in the serum of patients with hypothyroidism. Tikrit J Pure Sci. 2019;2019:70-3.
2. Feldt-Rasmussen U, Effraimidis G, Bliddal S, Klose M. Consequences of undertreatment of hypothyroidism. Endocrine. 2024;84(2):301-8. https://doi.org/10.1007/s12020-023-03460-1
3. Hadeed WA, Alhially Y, Bashi A. Comparison of thyroid function tests between splenectomised and non-splenectomised β-thalassemia major patients. Tik J of Pure Sci. 2015;20:61-6.
4. Bereda G. Definition, causes, pathophysiology, and management of hypothyroidism. Mathews Journal of Pharmaceutical Science. 2023;7(1):1-5.
5. England ML, Gerrard JM. Hypothyroidism, diabetes, and cardiovascular disease. Cardiometabolic Diseases: Elsevier; 2025. p. 239-48. https://doi.org/10.1016/B978-0-323-95469-3.00004-8
6. Al-harbawi DJT, Al-obaidi WML. Determination Of Hepcidin Concentration And Many Hematological And Biochemical Variations In Patients With Diabetes Type 2 Diabetes in Balad City. Tikrit Journal of Pure Science. 2017;22(3):1-6.
7. Kim HK, Song J. Hypothyroidism and diabetes-related dementia: Focused on neuronal dysfunction, insulin resistance, and dyslipidemia. International Journal of Molecular Sciences. 2022;23(6):2982. https://doi.org/10.3390/ijms23062982
8. Chen J, Wu L, Li Y. FGL1 and FGL2: emerging regulators of liver health and disease. Biomarker Research. 2024.
https://doi.org/10.1186/s40364-024-00601-0;12(1):53.
9. Wang C-C, Lin C-H, Chou H-W, Wang C-T, Liang Y-C, Wu H-T, et al. Compensatory Increase of Serum Hepassocin Protects Against Hyperthyroidism-Induced Hepatic Dysfunction. Biomedicines. 2023;11(7):1936. https://doi.org/10.3390/biomedicines11071936
10. Milek M, Moulla Y, Kern M, Stroh C, Dietrich A, Schön MR, et al. Adipsin serum concentrations and adipose tissue expression in people with obesity and type 2 diabetes. International journal of molecular sciences. 2022;23(4):2222.
https://doi.org/10.3390/ijms23042222
11. Liu Y, Qian S-W, Tang Y, Tang Q-Q. The secretory function of adipose tissues in metabolic regulation. Life Metabolism. 2024;3(2):loae003. https://doi.org/10.1093/lifemeta/loae003
12. Rasoulizadeh Z, Ordooei M, Akbarian E. Diagnostic options, physiopathology, risk factors and genetic causes of permanent congenital hypothyroidism: A narrative review. Caspian Journal of Internal Medicine. 2024;15(4):570. https://doi.org/10.22088/cjim.15.4.570
13. Wrońska K, Hałasa M, Szczuko M. The role of the immune system in the course of Hashimoto’s Thyroiditis: the current state of knowledge. International Journal of Molecular Sciences. 2024;25(13):6883. https://doi.org/10.3390/ijms25136883
14 Grimmichova T, Verespejova L, Urbaniova Z, Chovanec M, Hill M, Bilek R. Acquired hypothyroidism, iodine status and hearing impairment in adults: A pilot study. PloS one. 2025;20(1):e0305787. https://doi.org/10.1371/journal.pone.0305787
15. Ettleson MD, Bianco AC. Individualized therapy for hypothyroidism: Is T4 enough for everyone? The Journal of Clinical Endocrinology & Metabolism. 2020;105(9):e3090-e104.
doi:10.1210/clinem/dgaa430
16. Chaker L, Razvi S, Bensenor IM, Azizi F, Pearce EN, Peeters RP. Hypothyroidism (primer). Nature Reviews: Disease Primers. 2022;8(1). doi:10.1210/clinem/dgaa430
17. Wilson SA, Stem LA, Bruehlman RD. Hypothyroidism: diagnosis and treatment. American family physician. 2021;103(10):605-13.
18. Salvatore D, Porcelli T, Ettleson MD, Bianco AC. The relevance of T3 in the management of hypothyroidism. The Lancet Diabetes & Endocrinology. 2022;10(5):366-72.
19. Croce L, De Martinis L, Pinto S, Coperchini F, Dito G, Bendotti G, et al. Compared with classic Hashimoto’s thyroiditis, chronic autoimmune serum-negative thyroiditis requires a lower substitution dose of L-thyroxine to correct hypothyroidism. Journal of Endocrinological Investigation. 2020;43:1631-6.
https://doi.org/10.1007/s40618-020-01249-x
20. Liu H, Peng D. Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism. Endocrine Connections. 2022;11(2). DOI: https://doi.org/10.1530/EC-21-0002
21. Xue H, Xu R. The lymphocyte levels of Hashimoto thyroiditis patients were significantly lower than those of the healthy population. Frontiers in Endocrinology. 2025;16:1472856.
https://doi.org/10.3389/fendo.2025.1472856
22. Triolo M, Kwakernaak AJ, Perton FG, de Vries R, Dallinga-Thie GM, Dullaart RP. Low normal thyroid function enhances plasma cholesteryl ester transfer in Type 2 diabetes mellitus. Atherosclerosis. 2013;228(2):466-71.
https://doi.org/10.1016/j.atherosclerosis.2013.03.009
23. Abdelmoemen G, Khodeir SA, Zaki AN, Kassab M, Abou-Saif S, Abd-Elsalam S. Overexpression of hepassocin in diabetic patients with nonalcoholic fatty liver disease may facilitate increased hepatic lipid accumulation. Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets-Immune, Endocrine & Metabolic Disorders). 2019;19(2):185-8. https://doi.org/10.2174/1871530318666180716100543
24. Vemula SL, Aramadaka S, Mannam R, Narayanan RS, Bansal A, Yanamaladoddi VR, et al. The impact of hypothyroidism on diabetes mellitus and its complications: a comprehensive review. Cureus. 2023;15(6). DOI: 10.7759/cureus.40447
25. Kim TH, Hong D-G, Yang YM. Hepatokines and non-alcoholic fatty liver disease: linking liver pathophysiology to metabolism. Biomedicines. 2021;9(12):1903. https://doi.org/10.3390/biomedicines9121903
26. Pan J, Ding Y, Sun Y, Li Q, Wei T, Gu Y, et al. Associations between adipokines and metabolic dysfunction-associated fatty liver disease using three different diagnostic criteria. Journal of Clinical Medicine. 2023;12(6):2126.
https://doi.org/10.3390/jcm12062126
27. Elshinshawy S, Elhaddad H, Alem SA, Shaker O, Salam R, Yosry A, et al. The interrelation between hypothyroidism and non-alcoholic fatty liver disease: a cross-sectional study. Journal of Clinical and Experimental Hepatology. 2023;13(4):638-48. https://doi.org/10.1016/j.jceh.2023.03.004
28. Jiang M-Y, Man W-R, Zhang X-B, Zhang X-H, Duan Y, Lin J, et al. Adipsin inhibits Irak2 mitochondrial translocation and improves fatty acid β-oxidation to alleviate diabetic cardiomyopathy. Military Medical Research. 2023;10(1):63.
https://doi.org/10.1186/s40779-023-00493-5
29. Flier JS, Cook KS, Usher P, Spiegelman BM. Severely impaired adipsin expression in genetic and acquired obesity. Science. 1987;237(4813):405-8. https://doi.org/10.1126/science.3299706
30. Vasilenko M, Kirienkova E, Skuratovskaia D, Zatolokin P, Mironyuk N, Litvinova L, editors. The role of production of adipsin and leptin in the development of insulin resistance in patients with abdominal obesity. Doklady Biochemistry and Biophysics; 2017: Springer.
https://doi.org/10.1134/S160767291704010X
31. Bansal A, Honnapurmath VK, Singh A. Serum adipsin levels as a new marker in type 2 diabetes mellitus: A meta-analysis. International Journal of Diabetes in Developing Countries. 2025:1-7. https://doi.org/10.1007/s13410-025-01449-2
32. Gómez-Banoy N, Guseh JS, Li G, Rubio-Navarro A, Chen T, Poirier B, et al. Adipsin protects beta cells in diabetic mice and is associated with protection against type 2 diabetes in humans. Nature medicine. 2019;25(11):1739-47.
https://doi.org/10.1038/s41591-019-0610-4
33. Park J-H, Nguyen TN, Shim HM, Yu GI, Ha EY, Cho H. Identification of Adipsin as a Biomarker of Beta Cell Function in Patients with Type 2 Diabetes. Journal of Clinical Medicine. 2024;13(23):7351. https://doi.org/10.3390/jcm13237351
34. Emiral Ç, Buluş D, Yaşartekin Y, Akaydın S. Serum Adipsin Levels in Obese and Normal Weight Adolescents with Polycystic Ovary Syndrome. Journal of Gazi University Health Sciences Institute. 2024;6(3):107-16.
https://doi.org/10.59124/guhes.1604306
35. Byeon HJ, Chae MK, Ko J, Lee EJ, Kikkawa DO, Jang SY, et al. The role of adipsin, complement factor D, in the pathogenesis of Graves’ Orbitopathy. Investigative ophthalmology & visual science. 2023;64. https://doi.org/10.1167/iovs.64.11.13